News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Reason Why Merck & Co., Inc. (MRK) Just Spent $4 Billion On New Drugs For Hepatitis C


6/9/2014 8:16:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Wall Street has already declared a winner in the race to develop new treatments for hepatitis C, a virus that infects 3.2 million Americans that is the leading cause of liver transplantation in the United States. It’s Gilead Sciences GILD -4.07%. Everyone knows that Gilead’s Sovaldi, already the best drug launch ever with $2.3 billion in sales in its first quarter, is set to dominate this new market.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES